Second-line pemetrexed, docetaxel similarly effective for NSCLC

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1439, 2004-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cisplatin + pemetrexed as first-line therapy for advanced NSCLC

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer

By Scagliotti Giorgio  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2855-2866

Informa Healthcare

Access to resources Recommend Favorite

Docetaxel: clinical benefit in first-line treatment for NSCLC

By  

Inpharma, Vol. 1, Iss. 1348, 2002-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Irinotecan plus docetaxel a first-line option for NSCLC

By  

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Is pemetrexed cost effective for NSCLC in the US?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 611, 2010-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite